Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pohl

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cleveland Clinic Journal of Medicine|July 12, 2016
In Reply: Blood pressure targetsGeorge Thomas, Joseph V Nally, Marc A Pohl
Cleveland Clinic Journal of Medicine|March 15, 2016
Interpreting SPRINT: How low should you go?George Thomas, Joseph V Nally, Marc A Pohl
The American Journal of Cardiology|March 31, 2004
Relation of homocysteine and C-reactive protein to urinary albumin lossNiranjan Seshadri, Adrian W Messerli, Naveen Acharya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2011
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trialEdmund J Lewis, Julia B Lewis, Tom Greene, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2011
Pyridorin in type 2 diabetic nephropathyEdmund J Lewis, Tom Greene, Samuel Spitalewiz, et al.
Journal of the American Society of Nephrology : JASN|August 27, 2005
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitationsMarc A Pohl, Samuel Blumenthal, Daniel J Cordonnier, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cleveland Clinic Journal of Medicine|July 12, 2016
In Reply: Blood pressure targetsGeorge Thomas, Joseph V Nally, Marc A Pohl
Cleveland Clinic Journal of Medicine|March 15, 2016
Interpreting SPRINT: How low should you go?George Thomas, Joseph V Nally, Marc A Pohl
The American Journal of Cardiology|March 31, 2004
Relation of homocysteine and C-reactive protein to urinary albumin lossNiranjan Seshadri, Adrian W Messerli, Naveen Acharya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2011
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trialEdmund J Lewis, Julia B Lewis, Tom Greene, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2011
Pyridorin in type 2 diabetic nephropathyEdmund J Lewis, Tom Greene, Samuel Spitalewiz, et al.
Journal of the American Society of Nephrology : JASN|August 27, 2005
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitationsMarc A Pohl, Samuel Blumenthal, Daniel J Cordonnier, et al.
Pageof 1